A prediction model for successful increase of adalimumab dose intervals: analysis of the pragmatic open-label randomised controlled non-inferiority LADI trial

被引：0

作者：

Van Linschoten, R. ^{[1
,2
]}

Jansen, F. ^{[3
]}

Pauwels, R. ^{[2
]}

Smits, L. ^{[3
]}

Atsma, F. ^{[4
]}

Kievit, W. ^{[5
]}

de Jong, D. ^{[3
]}

de Vries, A. ^{[2
]}

Boekema, P. ^{[6
]}

West, R.

Bodelier, A. ^{[7
]}

Gisbertz, I. ^{[8
]}

Wolfhagen, F. ^{[9
]}

Romkens, T. ^{[10
]}

Lutgens, M. ^{[11
]}

van Bodegraven, A. ^{[12
]}

Oldenburg, B. ^{[13
]}

Pierik, M. ^{[14
]}

Russel, M. ^{[15
]}

de Boer, N. ^{[16
]}

Mallant-Hent, R. ^{[17
]}

ter Borg, P. ^{[18
]}

van der Meulen-de Jong, A. ^{[19
]}

Jansen, J. ^{[20
]}

Jansen, S. ^{[21
]}

Tan, A. ^{[22
]}

van der Woude, C. J. ^{[2
]}

Hoentjen, F. ^{[23
]}

机构：

[1] Franciscus Gasthuis Vlietland, Gastroenterol & Hepatol, Rotterdam, Netherlands

[2] Erasmus MC, Dept Gastroenterol & Hepatol, Rotterdam, Netherlands

[3] Radboud Univ Nijmegen, Med Ctr, Dept Gastroenterol & Hepatol, Nijmegen, Netherlands

[4] Radboud Univ Nijmegen, Med Ctr, IQ Healthcare, Nijmegen, Netherlands

[5] Radboud Univ Nijmegen, Med Ctr, Radboud Inst Hlth Sci, Dept Hlth Evidence, Nijmegen, Netherlands

[6] Maxima Med Ctr, Dept Gastroenterol & Hepatol, Eindhoven, Netherlands

[7] Amphia Hosp, Dept Gastroenterol & Hepatol, Breda, Netherlands

[8] Bernhoven Hosp, Dept Gastroenterol & Hepatol, Uden, Netherlands

[9] Albert Schweitzer Hosp, Dept Gastroenterol & Hepatol, Dordrecht, Netherlands

[10] Jeroen Bosch Hosp, Dept Gastroenterol & Hepatol, Shertogenbosch, Netherlands

[11] Elisabeth Tweesteden Hosp, Dept Gastroenterol & Hepatol, Tilburg, Netherlands

[12] Zuyderland Med Ctr, Dept Gastroenterol Geriatr Internal & Intens Care, Heerlen, Netherlands

[13] Univ Med Ctr Utrecht, Dept Gastroenterol & Hepatol, Utrecht, Netherlands

[14] Maastricht Univ, Med Cter, Dept Gastroenterol & Hepatol, Maastricht, Netherlands

[15] Medisch Spectrum Twente, Dept Gastroenterol & Hepatol, Twente, Netherlands

[16] Vrije Univ Amsterdam, Amsterdam Univ, Med Ctr, Dept Gastroenterol & Hepatol,AGEM Res Inst, Amsterdam, Netherlands

[17] Flevoziekenhuis, Dept Gastroenterol & Hepatol, Almere, Netherlands

[18] Ikazia Hosp, Dept Gastroenterol & Hepatol, Rotterdam, Netherlands

[19] Leiden Univ, Med Ctr, Dept Gastroenterol & Hepatol, Leiden, Netherlands

[20] OLVG, Dept Gastroenterol & Hepatol, Roterdam, Netherlands

[21] Reinier Graaf Gasthuis, Dept Gastroenterol & Hepatol, Delft, Netherlands

[22] Canisius Wilhelmina Hosp, Dept Gastroenterol & Hepatol, Nijmegen, Netherlands

[23] Univ Alberta, Div Gastroenterol Dept Med, Edmonton, AB, Canada

来源：

JOURNAL OF CROHNS & COLITIS | 2023年 / 17卷

关键词：

D O I：

暂无

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

P526

引用

页码：655 / 658

页数：3

共 50 条

[1] A Prediction Model for Successful Increase of Adalimumab Dose Intervals in Patients with Crohn's Disease: Secondary Analysis of the Pragmatic Open-Label Randomised Controlled Non-inferiority LADI Trial
van Linschoten, Reinier C. A.
Jansen, Fenna M.
Pauwels, Renske W. M.
Smits, Lisa J. T.
Atsma, Femke
Kievit, Wietske
de Jong, Dirk J.
de Vries, Annemarie C.
Boekema, Paul J.
West, Rachel L.
Bodelier, Alexander G. L.
Gisbertz, Ingrid A. M.
Wolfhagen, Frank H. J.
Romkens, Tessa E. H.
Lutgens, Maurice W. M. D.
van Bodegraven, Adriaan A.
Oldenburg, Bas
Pierik, Marieke J.
Russel, Maurice G. V. M.
de Boer, Nanne K.
Mallant-Hent, Rosalie C.
ter Borg, Pieter C. J.
van der Meulen-de Jong, Andrea E.
Jansen, Jeroen M.
Jansen, Sita V.
Tan, Adrianus C. I. T. L.
van der Woude, C. Janneke
Hoentjen, Frank
DIGESTIVE DISEASES AND SCIENCES, 2024, : 2165 - 2174
[2] Increased versus conventional adalimumab dose interval for patients with Crohn's disease in stable remission (LADI) a pragmatic, open-label, non-inferiority, randomised controlled trial
van Linschoten, Reinier C. A.
Jansen, Fenna M.
Pauwels, Renske W. M.
Smits, Lisa J. T.
Atsma, Femke
Kievit, Wietske
de Jong, Dirk J.
de Vries, Annemarie C.
Boekema, Paul J.
West, Rachel L.
Bodelier, Alexander G. L.
Gisbertz, Ingrid A. M.
Wolfhagen, Frank H. J.
Romkens, Tessa E. H.
Lutgens, Maurice W. M. D.
van Bodegraven, Adriaan A.
Oldenburg, Bas
Pierik, Marieke J.
Russel, Maurice G. V. M.
de Boer, Nanne K.
Mallant-Hent, Rosalie C.
ter Borg, Pieter C. J.
van der Meulen-de Jong, Andrea E.
Jansen, Jeroen M.
Jansen, Sita, V
Tan, Adrianus C. I. T. L.
van der Woude, C. Janneke
Hoentjen, Frank
LANCET GASTROENTEROLOGY & HEPATOLOGY, 2023, 8 (04): : 343 - 355
[3] Increased versus conventional adalimumab dose interval for patients with Crohn's disease in stable remission (LADI): a pragmatic, open-label, non-inferiority, randomised controlled trial (vol 8, pg 343, 2023)
van Linschoten, R. C. A.
Jansen, F. M.
Pauwels, R. W. M.
LANCET GASTROENTEROLOGY & HEPATOLOGY, 2023, 8 (04): : E4 - E4
[4] Successful reduction of overexposure in patients with rheumatoid arthritis with high serum adalimumab concentrations: an open-label, non-inferiority, randomised clinical trial
l'Ami, Merel J.
Krieckaert, Charlotte L. M.
Nurmohamed, Michael T.
van Vollenhoven, Ronald F.
Rispens, Theo
Boers, Maarten
Wolbink, Gerrit Jan
ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 (04) : 484 - 487
[5] Reduced versus maximum tolerated methotrexate dose concomitant with adalimumab in patients with rheumatoid arthritis (MIRACLE): a randomised, open-label, non-inferiority trial
Tamai, Hiroya
Ikeda, Kei
Miyamoto, Toshiaki
Taguchi, Hiroaki
Kuo, Chang-Fu
Shin, Kichul
Hirata, Shintaro
Okano, Yutaka
Sato, Shinji
Yasuoka, Hidekata
Kuwana, Masataka
Ishii, Tomonori
Kameda, Hideto
Kojima, Toshihisa
Taninaga, Takehiro
Mori, Masahiko
Miyagishi, Hideaki
Sato, Yasunori
Tsai, Wen-Chan
Takeuchi, Tsutomu
Kaneko, Yuko
LANCET RHEUMATOLOGY, 2023, 5 (04): : 215 - 224
[6] Dose reduction and withdrawal strategy for TNF-inhibitors in psoriatic arthritis and axial spondyloarthritis: design of a pragmatic open-label, randomised, non-inferiority trial
Celia A. J. Michielsens
Nadine Boers
Nathan den Broeder
Mark H. Wenink
Aatke van der Maas
Elien A. M. Mahler
Michelle L. M. Mulder
Désirée van der Heijde
Frank H. J. van den Hoogen
Lise M. Verhoef
Alfons A. den Broeder
Trials, 21
[7] Dose reduction and withdrawal strategy for TNF-inhibitors in psoriatic arthritis and axial spondyloarthritis: design of a pragmatic open-label, randomised, non-inferiority trial
Michielsens, Celia A. J.
Boers, Nadine
den Broeder, Nathan
Wenink, Mark H.
van der Maas, Aatke
Mahler, Elien A. M.
Mulder, Michelle L. M.
van der Heijde, Desiree
van den Hoogen, Frank H. J.
Verhoef, Lise M.
ven Broeder, Alfons A.
TRIALS, 2020, 21 (01)
[8] Psychotherapy for depression in older veterans via telemedicine: a randomised, open-label, non-inferiority trial
Egede, Leonard E.
Acierno, Ron
Knapp, Rebecca G.
Lejuez, Carl
Hernandez-Tejada, Melba
Payne, Elizabeth H.
Frueh, B. Christopher
LANCET PSYCHIATRY, 2015, 2 (08): : 693 - 701
[9] Lengthening adalimumab dosing interval in quiescent Crohn's disease patients: protocol for the pragmatic randomised non-inferiority LADI study
Smits, L. J. T.
Pauwels, R. W. M.
Kievit, W.
de Jong, D. J.
de Vries, A. C.
Hoentjen, F.
van der Woude, C. J.
BMJ OPEN, 2020, 10 (05):
[10] Disease activity guided dose reduction and withdrawal of adalimumab or etanercept compared with usual care in rheumatoid arthritis: open label, randomised controlled, non-inferiority trial
van Herwaarden, Noortje
van der Maas, Aatke
Minten, Michiel J. M.
van den Hoogen, Frank H. J.
Kievit, Wietske
van Vollenhoven, Ronald F.
Bijlsma, Johannes W. J.
van den Bemt, Bart J. F.
den Broeder, Alfons A.
BMJ-BRITISH MEDICAL JOURNAL, 2015, 350

← 1 2 3 4 5 →